Journey Medical (DERM) Status Update summary

Emrosi clinical and regulatory highlights

• Emrosi 40 mg, a novel oral minocycline, received FDA approval for treating inflammatory lesions of rosacea, showing statistically significant superiority over both placebo and Oracea in phase III trials.

• The drug demonstrated strong efficacy in reducing erythema and had a safety profile similar to placebo, with consistent results across age groups.

• Emrosi's unique formulation combines immediate and extended release minocycline, resulting in lower systemic exposure and potentially improved skin targeting.

• Publications of phase III and sub-antimicrobial studies are planned, with anticipated inclusion in consensus treatment guidelines.

Market opportunity and commercial strategy

• The U.S. rosacea market includes 16.5 million patients and 5.1 million prescriptions annually, with oral treatments representing over 700,000 prescriptions.

• Emrosi is positioned to capture a significant share of the oral market, leveraging an experienced dermatology sales force covering 83% of oral rosacea prescriptions.

• The product's list price is $1,298 for a 30-day supply, reflecting its clinical advantages over Oracea.

• The sales team targets high-prescribing dermatologists, aiming for rapid adoption within the first three months post-launch.

Go-to-market and marketing initiatives

• Four pillars drive adoption: direct promotion, HCP awareness, patient access, and refill adherence.

• Market research shows 88% of surveyed prescribers cite head-to-head data as the main reason to prescribe Emrosi, with 74% very likely to prescribe.

• Marketing will emphasize rapid efficacy, superior safety, and patient convenience, supported by before-and-after clinical images.

• Launch activities include presence at the AAD conference, speaker programs, e-sampling, and targeted digital advertising.